---
title: "GLAXOSMITHKLINE US TRADING LIMITED — Ownership Dossier"
canonical: https://whiteintel.dev/entity/dea88797-d6fb-50ff-9a3f-e1593b1d6286
json: https://whiteintel.dev/api/public/dossier/dea88797-d6fb-50ff-9a3f-e1593b1d6286
identifier: oo:GB-COH-11566030
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# GLAXOSMITHKLINE US TRADING LIMITED

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `oo:GB-COH-11566030`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/dea88797-d6fb-50ff-9a3f-e1593b1d6286  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/dea88797-d6fb-50ff-9a3f-e1593b1d6286  

## Ownership & control

### Owners / controllers

- **GLAXO GROUP LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/fb1d9c92-80b5-5f61-88b4-dbc4d71eaae8
- **GLAXO GROUP LIMITED** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/fb1d9c92-80b5-5f61-88b4-dbc4d71eaae8

### UBO chain (walk to the ultimate owner)

A **14-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Company profile (live · UK Companies House)

- **Company number:** `11566030`
- **Status:** liquidation
- **Type:** ltd
- **Incorporated:** 2018-09-12
- **Registered office:** C/O Bdo Llp, 5 Temple Square, Temple Street, Liverpool, L2 5RH
- **SIC:** 46460

### Officers

- [EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED](https://whiteintel.dev/entity/4401174d-4f25-5698-8e3a-3f933dd54455) — corporate secretary · appointed 2018-09-12
- LYNCH, Aidan — director · Irish · appointed 2019-09-10
- [THE WELLCOME FOUNDATION LIMITED](https://whiteintel.dev/entity/28855862-898c-512b-ab1c-45a367bd933a) — corporate director · appointed 2018-09-12
- ADAMS, Wendy — director · British · appointed 2021-03-11 · resigned 2024-12-31
- ALSTEENS, Benoit Marie — director · Belgian · appointed 2020-04-10 · resigned 2021-09-13
- BOX, Jonathan — director · British · appointed 2018-09-12 · resigned 2023-12-13
- COLLIER, Andrew James — director · British · appointed 2025-01-01 · resigned 2025-08-11
- GREEN, Jay Wade — director · Canadian · appointed 2018-10-22 · resigned 2020-02-26
- HEATHCOTE, Mark James — director · British · appointed 2018-09-12 · resigned 2025-08-11
- MILLAN, Gabriel — director · Spanish · appointed 2023-12-13 · resigned 2024-11-01
- STEWART, Yvonne Margaret, Dr — director · British · appointed 2021-09-13 · resigned 2025-08-11
- WALKER, Adam — director · British · appointed 2018-09-12 · resigned 2020-03-02
- WILKINSON, Neil Richard — director · British · appointed 2024-11-01 · resigned 2025-08-11
- [EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED](https://whiteintel.dev/entity/4401174d-4f25-5698-8e3a-3f933dd54455) — corporate director · appointed 2018-09-12 · resigned 2025-08-11

### Beneficial owners (Persons with Significant Control)

- [Glaxo Group Limited](https://whiteintel.dev/entity/fb1d9c92-80b5-5f61-88b4-dbc4d71eaae8) — 75–100% shares · corporate PSC · United Kingdom — since 2018-09-12

## Provenance

- OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/11566030
- companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/11566030

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **GLAXOSMITHKLINE US TRADING LIMITED**. Human view: https://whiteintel.dev/entity/dea88797-d6fb-50ff-9a3f-e1593b1d6286 · Structured JSON: https://whiteintel.dev/api/public/dossier/dea88797-d6fb-50ff-9a3f-e1593b1d6286._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._